Generics - AstraZeneca

Filter

Current filters:

AstraZeneca

Popular Filters

1 to 25 of 30 results

Generics maker IGI Laboratories acquires 18 AstraZeneca drugs

Generics maker IGI Laboratories acquires 18 AstraZeneca drugs

25-09-2014

New Jersey-based specialty generic company IGI Laboratories has acquired regulatory rights, related documents…

AstraZenecaGenericsIGI LaboratoriesLicensingUSA

Teva gets positive UK judgment in case against AstraZeneca

Teva gets positive UK judgment in case against AstraZeneca

03-09-2014

A positive judgment has been given by the UK High Court in support of Israeli generic drug giant Teva…

AstraZenecaDuoResp SpiromaxGenericsLegalPatentsRespiratory and PulmonarySymbicortTeva Pharmaceutical IndustriesUK

Actavis challenges AstraZeneca’s diabetes drug Onglyza patent in the USA

Actavis challenges AstraZeneca’s diabetes drug Onglyza patent in the USA

28-05-2014

Generics major Actavis yesterday confirmed that it has filed an Abbreviated New Drug Application with…

ActavisAstraZenecaDiabetesGenericsOnglyzaPatentsUSA

Amneal debuts generic Esomeprazole strontium in USA

07-01-2014

Privately-held US generics drugmaker Amneal Pharmaceuticals has announced the launch of generic esomeprazole…

Amneal PharmaAstraZenecaEsomeprazole MagnesiumGastro-intestinalsGenericsMarkets & MarketingNexiumNorth AmericaUSA

AstraZeneca wins damages from Apotex

AstraZeneca wins damages from Apotex

04-12-2013

Anglo-Swedish drug major AstraZeneca this morning said it welcomed the US District Court for the Southern…

ApotexAstraZenecaFinancialGastro-intestinalsGenericsNexium I.V.North AmericaPatentsPrilosec

AstraZeneca’s patent protection for Pulmicort Respules upheld by US court

AstraZeneca’s patent protection for Pulmicort Respules upheld by US court

31-10-2013

The US Court of Appeals for the Federal Circuit has reversed and remanded for further proceedings a trial…

AstraZenecaGenericsLegalNorth AmericaPulmicort Respules

Further savings expected following Australian Crestor patent decision, says GMiA

07-03-2013

In a decision brought down by the Australian Federal Court earlier this week, suppliers of generic medicines…

Asia-PacificAstraZenecaCardio-vascularCrestorGenericsPatentsPharmaceuticalPricing

US Court of Appeals confirms validity of AstraZeneca' Seroquel XR patent

15-02-2013

AstraZeneca announced that, on 14 February 2013, the United States Court of Appeals for the Federal Circuit…

AstraZenecaGenericsLegalNeurologicalNorth AmericaPatentsPharmaceuticalSeroquel XR

Slow-down of European bipolar therapy market set for short-term slowdown

04-07-2012

Patent expiry of key blockbuster atypical antipsychotic drugs is likely to cause a decline in growth…

AstraZenecaEuropeGenericsMarkets & MarketingNeurologicalPatentsPharmaceuticalPricingSeroquel

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

04-05-2012

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

US Court upholds AstraZeneca Seroquel XR patent

30-03-2012

In some good news for the company, Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced last night…

Anchen PharmaceuticalsAstraZenecaGenericsMylan LaboratoriesNeurologicalNorth AmericaPatentsPharmaceuticalSeroquel XRTorrent Pharmaceuticals

1 to 25 of 30 results

Back to top